Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Combination therapy for obesity and metabolic disease.

Gadde KM, Allison DB.

Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):353-8. doi: 10.1097/MED.0b013e3283304f90. Review.

PMID:
19625958
2.

Anti-obesity drugs.

Kushner RF.

Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. doi: 10.1517/14656566.9.8.1339 . Review.

PMID:
18473708
3.

Combination pharmaceutical therapies for obesity.

Gadde KM, Allison DB.

Expert Opin Pharmacother. 2009 Apr;10(6):921-5. doi: 10.1517/14656560902824152 .

4.

New drug targets for the treatment of obesity.

Powell AG, Apovian CM, Aronne LJ.

Clin Pharmacol Ther. 2011 Jul;90(1):40-51. doi: 10.1038/clpt.2011.82. Review.

PMID:
21654742
5.

How physician obesity specialists use drugs to treat obesity.

Hendricks EJ, Rothman RB, Greenway FL.

Obesity (Silver Spring). 2009 Sep;17(9):1730-5. doi: 10.1038/oby.2009.69.

6.

FGF21: a novel prospect for the treatment of metabolic diseases.

Kharitonenkov A, Shanafelt AB.

Curr Opin Investig Drugs. 2009 Apr;10(4):359-64. Review.

PMID:
19337957
7.

New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases.

Shehzad A, Ha T, Subhan F, Lee YS.

Eur J Nutr. 2011 Apr;50(3):151-61. doi: 10.1007/s00394-011-0188-1. Review.

PMID:
21442412
8.

Obesity pharmacotherapy from a regulatory perspective: overview and key challenges.

Hutchinson NI, Ryder SW.

Clin Pharmacol Ther. 2007 May;81(5):756-60. Review.

PMID:
17392723
9.

Drug discovery in the metabolic syndrome: context and some recent developments.

Suckling K.

Expert Opin Ther Targets. 2007 Jun;11(6):801-8. Review.

PMID:
17504017
10.

Sibutramine: current status as an anti-obesity drug and its future perspectives.

Sharma B, Henderson DC.

Expert Opin Pharmacother. 2008 Aug;9(12):2161-73. doi: 10.1517/14656566.9.12.2161 . Review.

PMID:
18671470
11.

Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.

Bays HE.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1429-45. doi: 10.1586/erc.09.123. Review.

PMID:
19900026
12.

Pharmacotherapy of obesity: emerging drugs and targets.

Chakrabarti R.

Expert Opin Ther Targets. 2009 Feb;13(2):195-207. doi: 10.1517/14728220802637063 . Review.

PMID:
19236237
13.

Combination treatment to CONQUER obesity?

Shah K, Villareal DT.

Lancet. 2011 Apr 16;377(9774):1295-7. doi: 10.1016/S0140-6736(11)60518-7. No abstract available.

PMID:
21497686
14.

Drug treatment of obesity: established and emerging therapies.

Isidro ML, Cordido F.

Mini Rev Med Chem. 2009 Jun;9(6):664-73. Review.

PMID:
19519492
15.

Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift?

Krentz AJ, Hompesch M.

Drugs. 2013 Oct;73(15):1649-51. doi: 10.1007/s40265-013-0123-2. No abstract available.

PMID:
24092613
16.

Pharmacotherapy for psychotropic drug-related weight gain.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2008 Jul;46(7):15-8. Review.

PMID:
18686592
17.

Report on the NIH Workshop on Pharmacologic Treatment of Obesity.

Atkinson RL, Hubbard VS.

Am J Clin Nutr. 1994 Aug;60(2):153-6.

PMID:
7913290
18.

Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.

Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S.

Expert Opin Pharmacother. 2009 Apr;10(6):1069-81. doi: 10.1517/14656560902775750 . Review.

PMID:
19364254
19.

Rational design of a combination medication for the treatment of obesity.

Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA.

Obesity (Silver Spring). 2009 Jan;17(1):30-9. doi: 10.1038/oby.2008.461.

20.

Challenges in the discovery and development of new agents for the treatment of obesity.

Staten MA.

Clin Pharmacol Ther. 2007 May;81(5):753-5. Review.

PMID:
17377527
Items per page

Supplemental Content

Support Center